Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Paroxetine (Primary)
- Indications Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2018 Planned number of patients changed from 96 to 80.